Australia Begins Mandatory UDI Implementation: What the TGA's New Requirements Mean for Medical Device Companies

What's Changed?

On 1 July 2026, Australia's Therapeutic Goods Administration (TGA) commenced the mandatory implementation of Unique Device Identification (UDI) requirements for higher-risk medical devices, beginning with Class IIb and Class III devices.

The new requirements are designed to improve the identification and traceability of medical devices throughout their lifecycle, supporting stronger post-market surveillance, faster safety actions, and greater transparency across Australia's healthcare system.

To support industry during the transition, the TGA has also introduced a streamlined Consent to Supply (CtS) process for sponsors that require additional time to meet certain UDI obligations.

Why This Change Matters

Unique Device Identification is becoming a global regulatory standard.

By assigning a unique identifier to medical devices, regulators, healthcare providers, and manufacturers can more effectively monitor products, manage recalls, improve traceability, and strengthen patient safety.

For companies supplying medical devices in Australia, compliance with the new UDI requirements is now an important component of regulatory readiness.

Who Needs to Pay Attention?

This regulatory change is particularly relevant for:

✔ Medical device manufacturers

✔ Australian sponsors

✔ Importers and distributors

✔ Regulatory affairs professionals

✔ Quality and compliance teams

✔ Companies marketing Class IIb and Class III medical devices in Australia

Organisations should evaluate how the new UDI obligations affect their product portfolios, labelling, and regulatory documentation.

What Companies Should Do Next

1. Assess Product Readiness

Identify which products are subject to the mandatory UDI requirements and confirm implementation timelines.

2. Review Labelling and Data Management

Ensure product labels, identifiers, and supporting regulatory records are aligned with the new UDI framework.

3. Evaluate Transition Needs

Where compliance cannot be achieved immediately, determine whether the TGA's Consent to Supply process may be appropriate during the transition period.

4. Strengthen Post-Market Systems

UDI is more than a labelling requirement; it supports more effective vigilance, recalls, and lifecycle management.

Organisations should ensure internal quality systems are prepared to support these responsibilities.

ARQon Insight

The introduction of mandatory UDI requirements represents more than a regulatory milestone.

It reflects a global shift toward greater transparency, stronger supply chain visibility, and more effective post-market oversight.

Companies that invest in robust product identification and data management today will be better positioned to meet evolving regulatory expectations across multiple international markets.

Global Regulatory Trend

Australia joins a growing number of regulatory authorities implementing UDI frameworks to improve medical device traceability and patient safety.

Similar initiatives have been introduced in jurisdictions including the United States, the European Union, and other international markets, highlighting a worldwide movement toward harmonised device identification systems.

For global manufacturers, developing a consistent UDI strategy across markets is becoming an essential element of long-term regulatory compliance.

Key Takeaway

Australia's mandatory UDI requirements mark a significant advancement in the country's medical device regulatory framework.

Manufacturers and sponsors should use this transition period to strengthen labelling, product data management, and compliance processes to ensure continued market access and support safer healthcare outcomes.

How ARQon Can Support

ARQon supports healthcare and life sciences companies with:

• Regulatory intelligence and monitoring

• Australian market access strategy

• UDI implementation readiness

• Medical device regulatory consulting

• Labelling and compliance support

• Global regulatory planning

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.